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1. Introduction
Historically benign liver tumors were encountered incidentally during laparotomy or more re‐
cently during laparoscopy at which time definitive histological diagnosis can be established.
However, with the utilization of advanced imaging modalities hepatic neoplasms have been in‐
creasingly identified, with a prevalence rate of up to 50% reported among the general popula‐
tion [1]. Among these incidental lesions, 83% were characterized as benign neoplasms, as
outlined in Table 1 [1-3]. Benign hepatic neoplasms represent a diverse group of tumors that de‐
velop from either epithelial or mesenchymal cell lines (Table 2), and while the frequency of such
lesions is not well documented, more than 50% are classified as hemangiomas [1]. Focal nodu‐
lar hyperplasia (FNH) and hepatic adenomas represent the next most frequently diagnosed be‐
nign tumors. A variety of additional exceedingly rare benign lesions have also been described
most of which are sufficiently infrequent enough to be classified as “fascinomas” [1].
Neoplasm Relative frequency
Hemangioma 52%
Focal nodular hyperplasia 11%
Metastatic tumor (TxNxM1) 11%
Hepatocellular adenoma 8%
Focal fatty infiltration 8%
Hepatocellular carcinoma 6%
Extrahepatic process (eg.,
abscess, adrenal tumor) 3%
Other benign hepatic process 1%
Table 1. Diagnostic frequency of incidentally identified solid liver neoplasms1,2,9
© 2013 Chamberlain and Oelhafen; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cell of origin Tumors
Epithelial
Hepatocellular Focal nodular hyperplasia (FNH)
Hepatocellular adenoma (HA)
Regenerative nodule
Cholangiocellular Biliary adenoma
Biliary cystadenoma
Other Epitheliod leiomyoma
Mesenchymal
Endothelial Hemangioma
Cavernous
Capillary
Hemangioendothelioma
Adult
Infantile
Mesothelial Solitary fibrous tumor
Benign mesothelioma
Fibroma
Adipocyte Lipoma
Myelolipoma
Angiomyelipoma
Miscellaneous
Tumors Biliary hamartoma
Table 2. Benign solid liver neoplasms1,9
Most benign tumors are asymptomatic which makes standardizing the work-up difficult. The
evaluation of incidental solid hepatic tumors should be individualized based upon the
patient’s age, sex, past medical history, medications, and associated clinical signs. Although
physical examination of the abdomen is typically unremarkable it may rarely reveal localized
tenderness and/or a palpable mass. Liver function tests are indicated though are seldom
abnormal in asymptomatic patients. Additional laboratory testing such as alpha-fetoprotein
(AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 and, lactate dehy‐
drogenases may also be ordered depending on the clinical scenario.
Substantial advancements and the widespread availability and use of modern imaging
modalities to diagnose and treat abdominal pain, has led to a marked increase in the identifi‐
cation of benign liver tumors. A full discussion of the advantages and disadvantages of
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individual imaging techniques is beyond the scope of this chapter but is outlined in Table 3.
Briefly, B-mode ultrasonography (US) can effectively differentiate cystic and solid neoplasms
and is usually the initial study of choice [4,5]. Contrast-enhanced computed tomography (CT)
provides greater sensitivity than US for determination of lesion number, size, and location [5,
6]. Magnetic resonance imaging (MRI) represents the most sensitive and specific study to
discriminate between various benign liver lesions, particularly when contrast agents are used
[5-7]. Finally, fluorodeoxyglucose positron emission tomography (18FDG-PET) can aid in the
differentiation of benign versus malignant tumors based on the metabolic activity of the lesion
[8]. Although modern imaging techniques can precisely diagnose the vast majority of inci‐
dental benign tumors, laparoscopic or open biopsy is necessary to exclude malignancy when
precise diagnosis remains elusive.
US = ultrasonography; CT = computed tomography; MRI = magnetic resonance imaging; T1 = T1-weighted MRI; T2 = T2-
weighted MRI; Tc-99m RBC = technetium-99m-labeled red blood cell; Tc-99m SC = technetium-99m sulfur colloid.
Table 3. Radiographic appearance of benign liver neoplasms1,9
Accurate diagnosis is essential to the appropriate management of hepatic neoplasms. Al‐
though patients may require surgical intervention for diagnostic purposes, few benign tumors
require surgical management for symptomatic relief. As such, surgical intervention for benign
tumors is primarily indicated (1) for definitive diagnosis when imaging is inconclusive, (2) to
prevent malignant transformation, such as in the case of hepatic adenoma, (3) to reduce the
risk of rupture and, (4) for the treatment of rare life-threatening complications as a result of
rupture or haemorrhage [9].
2. Hemangioma
Hemangioma is the most common benign mesenchymal neoplasm of the liver and occurs in
two variants, capillary and cavernous. Hepatic hemangiomas are identified in 0.4% to 20% of
all imaging studies preformed [10-14]. Hemangiomas are frequently discovered incidentally
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on autopsy studies with 60%-80% identified in individuals in their 4th- 6th decade of life
[12-16].The precise etiology of hemangiomas is poorly understood but they are generally
considered to be benign congenital hamartomas composed of disorganized venous vascula‐
ture separated by intervening fibrous tissue [17]. Hemangiomas vary greatly in size from a
few millimeters to over 50 cm, with the majority (up to 80%) less than 4 cm [1,12,18]. Although
most commonly solitary, up to 40% of patients with hemangiomas have multiple tumors [19].
Capillary hemangiomas are more prevalent than are cavernous hemangiomas [1,20]. However,
these hypervascular lesions are typically small (2 cm) and are rarely clinically significant [1].
As such, the management of capillary hemangiomas requires the exclusion of malignancy and
patient reassurance that routine surveillance is not necessary in the absence of symptoms [9].
Cavernous hemangiomas are far more often clinically relevant than capillary hemangiomas.
The incidence of cavernous hemangiomas is 3 times greater among women than men, with a
mean age of 45 years [12,16]. Whether this reflects a true increase in incidence or a result of
more frequent imaging amongst females remains unclear as evident by one autopsy series in
which there was a nearly equal sex incidence [1,21]. Although no link between oral contra‐
ceptive pill (OCP) use and hemangioma incidence has been established, early studies suggest
a link between OCP use and increased hemangioma size at initial presentation [18].
3. Clinical presentation
The most frequently reported symptoms of liver hemangiomas include abdominal pain, nau‐
sea, vomiting, early satiety, and prolonged fever [1,22]. Most symptoms of hepatic hemangio‐
ma are attributable to rapid expansion, thrombosis, or infarction, resulting in inflammation or
stretching of Glisson’s capsule [1]. Large hemangiomas (> 10 cm) may occasionally present as a
non-tender palpable mass in the right upper quadrant, however physical exam more often re‐
veals only vague abdominal tenderness without a mass [1,23]. Occasionally, a bruit maybe de‐
tected over the liver. Evidence of intratumoral or intraperitoneal rupture may be reflected by
hemoperitoneum and subsequent shock, which requires emergent surgical intervention. Rare‐
ly biliary colic, obstructive jaundice, gastric obstruction, torsion of a pedunculated lesion, pul‐
monary embolism, spontaneous intraperitoneal hemorrhage, and consumptive coagulopathy
have been reported [22,24,25]. Kasabach-Merritt syndrome, which was originally used to de‐
scribe thrombocytopenia and afibrinogenemia associated with hemangiomas on the skin and
spleen of infants, is frequently used to define hepatic hemangioma patients with severe throm‐
bocytopenia and concomitant consumptive coagulopathy [26].
4. Pathology
Hemangiomas are typically well demarcated from surrounding hepatic tissue, which often
permits surgical enucleation [27]. In tumors not well demarcated, the tumor-parenchymal
interface defines the ease with which enucleation versus formal resection is required. Four
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interface variants between the hemangioma and hepatic parenchyma have been described.
The “fibrolamellar” interface is characterized by a capsule-like fibrous ring of various thickness
and is the most common [9]. The involved veins parallel the periphery of the hemangioma or
traverse the fibrous lamella. The healthy hepatic parenchyma is often atrophic and a plane
between the hemangioma and uninvolved liver tissue is well defined. A second variant, the
“compression” interface consists of a hemangioma in which the periphery of the neoplasm is
well demarcated despite the absence of a fibrous lamella [1]. An “interdigiting” pattern lacks
a fibrous lamella and instead is replaced by an ill-defined plane between the vascular channels
of the hemangioma and uninvolved hepatic parenchyma [1]. Finally, an “irregular” or
“spongy” interface occur when the hemangioma appears to intercalate into the surrounding
hepatic parenchyma [1]. Despite the invasive appearance of this variant, hemangiomas do not
possess any malignant potential.
The diagnosis of cavernous hemangioma is generally easy to establish with modern imaging
techniques. However, in some instances atypical hemangiomas may be confused for other
pathology, including but not limited to, hemorrhagic telangiectasia (Osler-Rendu-Weber),
hemangioendothelioma, and peliosis hepatis [9]. When diagnosis remains unclear, indeter‐
minate lesions should be managed surgically as percutaneous biopsy may result in uncon‐
trollable hemorrhage [1].
5. Radiographic evaluation
Accurate radiographic diagnosis of hepatic hemangioma is essential since once definitive
diagnosis is established no additional intervention is typically required [9]. Radiographic
evaluation is largely dictated by clinical presentation as most hemangiomas are discovered
incidentally on imaging studies completed for unrelated symptomology and/or pathology.
Depending on the initial degree of diagnostic certainty additional imaging maybe superfluous.
B-mode ultrasonography is typically the initial imaging study performed [1]. On US heman‐
giomas appear as a homogenous hyperechoic mass that is well demarcated from surrounding
liver parenchyma [1,28,29]. The addition of duplex US provides additional information
regarding peripheral blood flow and central pooling of venous blood [1,28]. As malignant
lesions may demonstrate similar acoustic patterns, additional imaging modalities are often
required for definitive confirmation. On contrast enhanced compute tomography (CE-CT)
hemangiomas initially appear as hypodense masses with a pattern of irregular peripheral
nodular enhancement following initial injection of contrast [30,31]. Delayed venous images
subsequently demonstrate characteristic central venous filling of the hypodense mass [30,31].
Magnetic resonance imagining (MRI), though rarely needed for diagnosis of most hemangio‐
mas, is the most sensitive and specific modality for the detection and diagnosis of hemangioma
[6,32]. T-1 weighted images reveal a smooth well-demarcated homogenous isodense mass,
whereas T-2 weighted studies demonstrate a hyperdense pattern [33,34]. The administration
of intravenous gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) contrast results in
the pathognomonic pattern of peripheral nodular enhancement with central filling on delayed
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images [1,35,36]. This enhancement pattern is typical of most hemangiomas > 2 cm [37].
Hemangiomas < 2 cm may demonstrate rapid uniform enhancement which is indistinguish‐
able from hypervascular hepatocellular carcinoma (HCC) [37]. 18F-FDG PET scan may be useful
for differentiation between benign and malignant hepatic tumors [38]. Studies have shown
that the activity of both glucose-6-phosphatase and glucose transporters are increased in HCC
resulting in decreased uptake of 18F-FDG in hemangiomas as compared to HCC [8]. Histori‐
cally, technetium-99 labeled red blood cells scintigram (Tc-99 RBC scan) was the gold standard
for the diagnostic evaluation of hemangiomas, but technological advancements in axial
imaging has led to a decline in the reliance on RBC scintigraphy [31,39]. Finally, selective
hepatic angiography typically yields a characteristic neovascular “corkscrewing” appearance
with rapid central filling from the neovascular periphery described as “cottonwool” [1].
Despite these characteristic findings, the high diagnostic yield of less invasive modalities
makes arteriography rarely necessary.
6. Diagnosis & treatment
The majority of hemangiomas are asymptomatic, particularly those lesions < 1.5 cm in size [1].
Although hemangiomas can grow to great sizes, they generally do not compromise liver
function and as such liver function tests are often normal. In rare instances thrombosis or
intraparenchymal hemorrhage may occur acutely affecting liver function tests. Spontaneous
rupture of hepatic hemangiomas is an exceptionally rare event with a review of the literature
revealing less than 30 cases of spontaneous rupture since 1898. Given the low yet significant
risk of bleeding, fine needle aspiration (FNA) should be avoided [1]. As a rule, biopsy is only
indicated if a histologic diagnosis is unclear or will alter planned treatment, thus in the absence
of clinical symptoms the most appropriate treatment strategy is careful observation [1].
Surgical resection should be considered in patients with disabling pressure or pain suggestive
of extrinsic compression of adjacent structures, in those experiencing acute symptoms related
to rupture, or when malignancy cannot be ruled out [22,40]. In general clinical symptoms
increase concurrently with tumor size, with most symptomatic tumors having a mean size of
10 ± 8 cm as compared with 6.8 ± 5.8 cm for asymptomatic lesions [41].
Surgical intervention should be approached no differently than for treatment of other hepatic
tumors. It is essential that surgeons possess an extensive knowledge of the anatomy and
vascular supply of the liver. The extent of hepatic resection required is directly related to the
anatomic location of the lesion and its proximity to surrounding vasculature. Thus, the location
of the lesion will largely dictate the operative approach hence a full evaluation of the tumor’s
extent is critical. Large central lesions which border the inferior vena cava, hepatic outflow
tract, or the portal vein, may pose an exorbitant surgical risk and as such may not allow for
resection [1].
While enucleation is often indicated, formal resection is required in certain instances. Recall it
is the histological features of the tumor-parenchymal interface which defines how easily a
parenchymal-sparing technique may be utilized. Unlike malignant lesions, resection of
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hemangiomas does not necessitate removal of a margin of normal tissue with the tumor.
Enucleation is carried out by careful dissection within the proper plane between the hepatic
parenchyma and tumor. Division and ligation of the principal hepatic artery should be
completed early in the operation as this often results in significant tumor decompression
thereby facilitating resection [1]. The majority of hemangiomas are contained within a tough
fibrous capsule which can be clamped and used for retraction purposes [1]. As hepatic venous
branches are encountered extending from the lesion they should be controlled with clips or
ties [1]. Presently, mortality outcomes for resection and enucleation are comparable [42].
Hepatic artery ligation for treatment of hemangioma has also been described anecdotally [9].
Although its benefits are likely transient, hepatic artery embolization and/or ligation play a
pivotal role only in the temporary management of uncontrolled hemorrhage from rupture
[43,44]. Finally, radiation therapy for symptomatic hemangiomas has also been reported.
Though data validating the use of radiotherapy is limited, it seems a reasonable approach for
symptomatic hemangioma where surgical intervention is clearly contraindicated.
7. Special issue: Hemangioma in children
Hepatic  hemangiomas of  infancy and childhood differ  substantially in their  appearance,
presentation, and progression than those in adults [1]. These lesions are frequently large
and symptomatic.  In contrast to adult  hemangiomas, the risk of spontaneous rupture in
infancy is  greater [1].  Similarly,  Kasabach-Merritt  syndrome occurs more frequently and
results more often in death among affected infants.  As a result of the numerous venous
lakes within these lesions, which serve as siphons for a large proportion of the total car‐
diac  output,  severe  congestive  heart  failure  and  death  may  result.  Initial  treatment  of
high  output  cardiac  failure  in  children  includes  oxygen,  diuretics,  digitalis,  corticoste‐
roids,  hepatic artery ligation, and radiation therapy [2,  45-48].  Contrary to the conserva‐
tive  management  of  adult  hemangiomas,  hemangiomas  of  infancy  and childhood more
frequently require life-saving surgical intervention.
8. Focal nodular hyperplasia
Focal nodular hyperplasia (FNH) is the second most common benign hepatic lesion [20]. FNH
is found predominately in women (in a ratio of 8-9:1) between the ages of 20-50 years, and has
a prevalence of 4 - 8% in the general population [49,50]. Similar to hemangiomas, the prevalence
of FNH has markedly increased over the past several decades, which likely reflects the
proficiency and widespread use of advanced imaging modalities [1].
Although Klatskin (1977) and Vana (1979) each reported an association between OCP use and
the development of FNH, the high frequency of FNH in the absence of OCP use suggests no
causal relationship [32,51]. However, enlargement of FNH lesions has been described in the
setting of pregnancy and long-term OCP use [52]. While the etiology of these lesions has not
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yet been clearly delineated, it has been suggested that FNH is a hyperplastic polyclonal
response of normal hepatic parenchyma to localized areas of increased arterial perfusion [53].
Expectantly, FNH has been found in association with vascular disorders and malformations
including hereditary hemorrhagic telangiectasia, hemihypertrophy Klippel-Trenaunay-
Weber syndrome, and congenital absence of the portal vein [49,54-57].
While typically small (< 5 cm), FNH lesions have been reported as large as 19 cm [48,50]. The
majority of FNH lesions are solitary in nature (80%-95%), although up to 20% of individuals
are reported to have multiple lesions [1, 48, 50]. When multifocal, FNH often occurs in
conjuncture with other benign hepatic lesions including hemangiomas [58].
9. Clinical presentation
FNH is frequently asymptomatic with up to 75% of lesions discovered incidentally dur‐
ing radiologic workup, laparotomy, or laparoscopy for unrelated pathology [59].  Similar
to hepatic  hemangiomas,  spontaneous rupture is  extremely rare as illustrated by Cham‐
berlain et.  al  (2003)  management of  33 patients  with FNH where no ruptures were evi‐
dent  [9].  Large,  peripheral,  pedunculated  lesions  may  result  in  a  palpable  mass
associated with abdominal pain and/or fullness, but acute symptoms associated with rup‐
ture, necrosis, or infarction are a rarity.
10. Pathology
Macroscopically FNH is a firm pale to red colored lesion with sharp margins. Lesions are
typically small, pedunculated, and peripherally located. Unlike hemangiomas and hepatic
adenomas, FNH lack a capsule. Histologically FNH appears as regenerative nodules making
histopathological differentiation from cirrhosis difficult. Lesions contain normal hepatic
elements with a haphazard arrangement of cords and sinusoids [5]. Proliferating bile ducts,
fibrous septae, Kupffer cells, and sinusoids are typically present in FNH, and are characteris‐
tically absent in hepatocellular adenomas [13,50,59]. Generally FNH contain a large artery with
multiple branches radiating through disorganized fibrous septa to the periphery. This
radiating arterial pattern produces a spoke and wheel image on angiography and is responsible
for the central scar appearance on radiographic imaging studies [60,61].
11. Radiographic imaging
Definitive diagnosis of FNH can be challenging. FNH lesions are well visualized on US but
are highly variable and exhibit no distinct characteristic features. Helical CE-CT reveals a well-
demarcated lesion that is often isodense [29]. However, during the portal venous phase the
pathognomonic central scar may be appreciated. Distinguishing FNH on standard MRI can
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prove challenging as the lesion is composed of the similar elements as the normal liver
parenchyma. FNH may appear isointense with a central scar on T-1 and T-2 weighted imaging
[62]. MRI with Gd-DTPA demonstrates a hyperintense lesion early, which becomes isointense
with central scar enhancement on delayed imaging [63-65]. The use of reticuloendothelial
agents including Ferridex, which is taken up selectively by Kupffer cells, increases the
specificity of both CT and MRI imaging [1]. Technetium-99-labeled sulfur colloid scintigraphy
may prove helpful in demonstrating the presence of Kupffer cells within the FNH lesion,
however this finding is not specific enough for definitive diagnosis [1,66,67]. Angiography,
though rarely indicated for the diagnosis of FNH, usually demonstrates a hypervascular mass
with a single central artery and enlarged peripheral vessels in a “spoken wheel” appearance
[66-68]. Finally, 18F-FDG PET can aid in the differentiation between benign and malignant
lesions, but it is neither sensitive nor specific enough for diagnosis of FNH [8,38].
12. Diagnosis & treatment
The natural  course of an FNH lesion is generally indolent with minimal risk of rupture
or  complication.  Laboratory testing generally  reveals  normal  liver  function tests  and al‐
pha-fetoprotein levels, although minor elevations in aspartate and alanine aminotransfer‐
ase, alkaline phosphatase, and gamma glutamyl transpeptidase may occasionally be seen.
Definitive diagnosis  of  FNH in an asymptomatic  patient  warrants conservative manage‐
ment  and includes  close  observation with  repeat  imaging every  four  to  six  months  [9].
When radiology is equivocal, most surgeons still choose close observation with follow-up
studies  preformed every three  to  four  months.  Biopsy is  generally  not  indicated,  as  re‐
sults are seldom diagnostic [69].
Although it may be impossible to distinguish FNH from a well-differentiated HCC without
surgical excision, FNH tumors do not undergo malignant transformation. Thus indications for
surgical intervention should be limited to those situations where there is a change in the size
or number of lesion(s), a change in the intensity of symptoms, or where classic imaging
characteristics are absent and diagnostic dilemma remains [70]. Hence, the role of the surgeon
is typically limited to patient reassurance and close observation [9].
13. Hepatic adenoma
Hepatic adenomas are identified predominately in women of reproductive age [49]. The
estimated prevalence of hepatic adenomas within the general population on postmortem
exams is approximately 1% [10]. Etiologically, hepatic adenomas are of epithelial origin. Unlike
hepatic hemangiomas and FNH, a clear association between the use of OCPs and hepatic
adenomas has been established. First described in 1973, multiple studies have documented a
reciprocal relationship between OCP use and adenoma incidence based on estrogen dose and
exposure time [71-75]. Approximately 90% of individuals with adenomas have previous OCP
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exposure [1]. The prevalence of hepatic adenomas is estimated at 1 per 1,000,000 among women
who have never used OCP as compared with 30-40 per 1,000,000 amongst long-term OCP users
[72,76]. OCPs also affect the course of disease progression as lesions are generally larger, more
numerous, and more likely to bleed than tumors in OCP-naïve individuals [32,75,77,78].
Adenoma regression has been observed in patients after discontinuation of OCP with recur‐
rence ensuing during pregnancy and/or OCP re-administration [72,79,-82]. Despite these
findings, the mechanism by which estrogen therapy affects the development and course of
hepatic adenomas has yet to be clearly elucidated.
Hepatic adenomas are typically small (< 5 cm), soft, solitary lesions but may be multiple in up
to 30% of cases [9]. Of note, hepatic adenomatosis disease, defined as the presence of >10
lesions, is a distinct disease entity from that of hepatic adenoma and as such will not be
described in further detail [83]. Hepatic adenomas have been associated with type I glycogen
storage disease, galactosemia, Klienfelter’s syndrome, and Turner’s syndrome as well as with
androgen, domiphene, danazol and growth hormone use [1,84-86]. Although hepatic adeno‐
mas are benign, these lesions have been associated with spontaneous hemorrhage, rupture,
and malignant transformation, making prognosis more grave than that of other benign hepatic
tumors [5,87].
14. Clinical presentation
Since  adenoma and FNH both present  in  women of  reproductive  age and have similar
radiographic  appearances  they  are  frequently  confused.  Differential  diagnosis  is  critical
given that the recommended treatment of each respective lesions differs. Hepatic adeno‐
mas are most often diagnosed as a result of imaging done for unrelated pathology or fol‐
lowing workup of a palpable abdominal mass (30% patients)  [88].  Occasionally episodic
pain  may be  evident  as  a  result  of  an  enlarged liver,  intratumoral  bleed,  or  tumor  ne‐
crosis [9].  Up to 33% of patients with hepatic adenomas present with acute rupture and
concomitant intraperitoneal bleeding [1].  The development of acute severe pain associat‐
ed with hypotension reflects spontaneous rupture and carries a 20% mortality rate if not
appropriately identified and treated [32,89-91].
15. Pathology
Grossly hepatic adenomas appear as smooth, soft, and pale yellow tumor on cut surface [1].
These lesions often contain prominent blood vessels that have a high potential for rupture and
hemorrhage [1]. As adenomas lack a fibrous capsule intraparenchymal bleeding may occur,
which frequently results in a variegated appearance.
Microscopically hepatic adenomas appear as well circumscribed lesions composed of monot‐
onous sheets of hepatocytes laden with glycogen and lipids [5]. These lesions lack normal
hepatic architecture and demonstrate thickened trabeculae interspersed with sinusoids and
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prominent thin walled vessels [1,5]. Biliary ducts and portal tracts are distinctly absent from
adenomas.
While the malignant potential of adenomas remains controversial, several authors have
reported a low (5%) yet consistent risk of transformation [87]. Histological differentiation
between well differentiated HCC and adenoma can be difficult, especially in the presence of
fibrolamellar HCC which is also more common in women of reproductive age. This issue is
further explained in situations in which HCC and hepatic adenoma have been found adjacent
to one another [61,50,89,92,93].
16. Radiological imaging
Although radiographic evaluation is important for complete workup of hepatic adenoma
radiographic features are often nonspecific [94]. As such, despite the use of multiple imaging
techniques, diagnosis often remains equivocal. Ultrasound exhibits a mixed echogenic pattern
with an overall heterogeneous appearance [1,29]. Lesions appear hyperechoic as a result of
their high lipid content with a heterogeneous pattern reflecting intratumoral hemorrhage and
necrosis [95]. CE-CT imaging is frequently utilized for adenoma visualization and typically
demonstrates a hypo- to isodense lesion as a result of low attenuation on non-contrast phase
[1]. A variegated appearance with peripheral enhancement during the early contrast phase
with subsequent centripetal flow during the venous phase may be apparent, however CT can
demonstrate a spectrum of disparate findings [96]. MRI findings for hepatic adenoma are
similar to those on CT. Due to the high fat and glycogen content, adenomas are usually well
demarcated on MRI imaging [29]. While most adenomas appear iso- to hyperintense on both
T-1 and T-2 weighted images, findings are highly variable [1,97]. The administration of contrast
agents including gadolinium or gabodenate dimeglumine (Gd-BOPTA) results in early
markedly uniform enhancement on arterial phase, which subsequently becomes isodense on
the portal venous phase [98]. The use of 18FDG PET scan may also aid in the differentiation of
benign versus malignant disease in which where adenomas demonstrate poor uptake of 18FDG
as compared to HCC [8,38].
Additional  imaging  modalities  infrequently  used  include  technetium-99  sulfur  colloid
scanning. This imaging modality is particularly useful in differentiating between hepatic
adenoma and FNH, as  hepatic  adenomas lack bile  duct  components  and frequently ap‐
pear as a “cold nodules” on imaging [99]. Occasionally however, a minority of lesions do
take  up  the  sulfur  colloid,  rendering  them  indistinguishable  from  FNH  [99].  Although
rarely utilized, angiography typically reveals hypervascular lesions with areas of hemor‐
rhage and necrosis [1,28].
17. Diagnosis & treatment
In the absence of acute hemorrhage, serological tests rarely assist in diagnosis. Liver function
tests and tumor makers including CEA, alpha-fetoprotein, and CA 19-9 are invariably normal.
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Hepatic adenomas pose a greater risk for rupture (33%) and malignant transformation (5%)
than do other benign hepatic lesions [9,87]. As such all patients with suspected or confirmed
hepatic adenoma > 3 cm should undergo enucleation or surgical resection [1,100]. The
approach to surgical excision should be as previously described. Since all adenomas are
suspected to harbor malignancy an adequate margin of normal parenchyma should be taken
[1]. When surgical exploration is not feasible angiographic embolization or ligation can provide
temporary yet life saving relief.
As a result of the relationship between OCP and adenoma incidence, it is recommended that
all individuals suspected of having an adenoma discontinue the use of OCP immediately and
indefinitely [1,61]. Patients should also be advised against pregnancy until after adenoma
resection, as the growth and rupture risk of hepatic adenomas is highly unpredictable during
gestation [101]. Yearly follow-up with imaging is advised among all patients where a causal
link between OCP use and adenoma is absent [9]. As a result of improved safety of hepatic
resection and the use of minimally invasive techniques in hepatectomy it is suggested that all
hepatic adenomas > 3 cm be resected [1,100]. In patients with significant contraindications to
surgical intervention, OCP should be discontinued and the patient enrolled in an ongoing
surveillance program [9].
18. Additional liver tumors
18.1. Epithelial tumor
Biliary hamartomas
Bile duct adenomas and hamartomas are common tumors. Bile duct adenomas appear as small,
white, solitary, subcapsular masses [1]. They are defined histologically by narrow lumen bile
ducts surrounded by fibrosis. Hamartomas appear as small gray-white nodules that lie just
beneath the capsule of the liver [102]. Biliary hamartomas are frequently multifocal and are
characterized microscopically by the presence of dilated mature bile ducts surrounded by
fibrous tissue [1]. These lesions are especially important as they are frequently misinterpreted
as metastatic tumor by the operating surgeon. This notion heightens the importance of
confirmatory diagnosis to rule out malignancy for all hepatic lesions. Precise diagnosis is most
important in situations in which the presence of a metastatic liver disease will alter the
proceedings of a planned operation.
18.2. Mesenchymal tumors
Solitary fibrous tumor (other names include benign mesothelioma or fibroma)
Solitary fibrous tumors (SFT) are rare mesenchymal tumors that are frequently mistaken for
metastatic lesions as a result of their radiographic and intra-operative appearance. Grossly
SFT’s appear as white-to-gray lesions and can vary greatly in size ranging from 2 – 20 cm in
diameter [1]. Despite their large size, most SFT’s remain asymptomatic. Histologically, most
have a classic short storiform pattern and display an absence of cellular atypia, mitoses,
Hepatic Surgery290
and/or necrosis [1]. However when malignant, SFTs frequently possess a high mitotic rate and
marked cellular atypia. Immunohistochemically SFTs display a strong positive staining for
vimentin and CD-34 [1]. Since definitive histologic examination is required for diagnosis of
either a benign or malignant SFT, surgical resection is indicated in nearly all circumstances.
Lipoma, myelolipoma, or angiomyelipoma
Similar to several other benign hepatic lesions, most benign fatty hepatic tumors are identified
at the time of autopsy with only isolated reports of histological diagnosis following operative
resection [13]. Multiple variants including angiolipoma, myelolipoma, and angiomyolipoma
have been described [13,103]. Additionally, “pseudolipomas” have been described as lesions
in which there is an extracapsular fatty tumor with involutional changes. It is probable that
this lesion results when a free-floating piece of fat becomes entrapped between diaphragm and
liver surface [1,10]. In most situations definitive diagnosis requires surgical resection to exclude
malignancy.
Mesenchymal Hamartomas
Mesenchymal hamartomas are exceedingly rare congenital liver tumors which occur most
frequently in infants under 1 year of age [9,104]. Microscopically these lesions demonstrate a
myxoid background of highly cellular embryonal mesenchyme with haphazard groupings of
bile ducts, cysts, and hepatic cells [105]. Generally, the cystic element is the most prominent
feature resulting in a characteristic “honeycomb” appearance [106]. In contrast to biliary
hamartomas, which are clinically insignificant, mesenchymal hamartomas can significantly
impair hepatic function as a result of their large size [106]. Although benign, these lesions can
result in death due to mass effect and/or hepatic insufficiency [1]. Thus, all suspected mesen‐
chymal hamartomas should be completely excised when possible. If complete surgical excision
cannot be achieved surgical debulking may be sufficient as there have been no reports of
recurrence after an incomplete surgical resection to date [107].
Myxoma
Myxomas are exceptionally uncommon benign lesions of the liver. To date fewer than five
cases have been reported [9,58,108]. These lesions arise from primitive connective tissue.
Histologically myxomas demonstrate a myxoid matrix with scattered proliferation of connec‐
tive tissue cells [108]. Similar to other types of hepatic tumors described above, surgical
resection is generally indicated to exclude malignancy.
Teratoma
Primary teratomas are remarkably rare benign hepatic lesions. A review of the literature
revealed only 7 reports to date, with the majority of lesions occurring in children [109].
Secondary hepatic teratomas have been observed following systemic chemotherapy adminis‐
tration for treatment of testicular cancer [1]. Teratomas arise from pluripotent cells and
frequently contain components from all three germ layers. Teratomas are typically encapsu‐
lated cystic lesions that are easily resectable [1,110]. Imaging characteristics reflect tissue
heterogeneity and are often non-specific [110]. Surgical resection of hepatic teratomas is
indicated to exclude malignancy.
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19. Conclusion
A thorough understanding of the natural history and accurate histologic diagnosis are
fundamental to appropriate management of patients with benign liver tumors. Although
advancements in imaging have drastically improved the detection and characterization of both
benign and malignant liver neoplasms, the ultimate burden of responsibility for diagnosis and
treatment remains that of the surgeon. Ongoing improvements in perioperative care and
surgical techniques, coupled with increased surgical experience presently permit hepatic
resection to be performed with a high level of safety. Despite these developments, a conser‐
vative approach including close observation with serial examination and imaging seems most
appropriate for asymptomatic patients in which malignancy is not suspected.
Symptomatic patients without medical or anatomic contraindication to a major hepatic
resection, as well as patients in whom a malignancy cannot be excluded (including individuals
with adenomas > 3 cm), should be considered for surgical intervention. Preoperative needle
biopsy is frequently contraindicated due to a high risk of rupture and hemorrhage, and
therefore should only be considered after exclusion of hemangioma. Additionally, it is
important to note that distinguishing particular lesions (especially adenoma and FNH) on
needle biopsy is exceedingly difficult. As such caution should exercised when using this
information to make clinical evaluations. Excisional biopsy of small and peripheral lesions and
adequate wedge incision biopsy of large lesions should permit the pathologist to make an
accurate histologic diagnosis and exclude a malignancy. If doubt remains, formal hepatic
resection is indicated.
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